Estimating the odds ratio when exposure has a limit of detection

International Journal of Epidemiology

Volumn 38, Issue 6, 2009, Pages 1674-1680

  Cole, Stephen R ^a   Chu, Haitao ^a   Nie, Lei ^b   Schisterman, Enrique F ^c  

^a IL   (United States)

^b Federal Drug Administration   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Biomarkers; Epidemiologic methods; Limit of detection; Statistical method

Indexed keywords

VIRUS RNA; BIOLOGICAL MARKER;

BIOMARKER; CONFIDENCE INTERVAL; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS; MAXIMUM LIKELIHOOD ANALYSIS;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERMETHOD COMPARISON; MALE; MAXIMUM LIKELIHOOD METHOD; PRIORITY JOURNAL; RISK ASSESSMENT; SIMULATION; VIRUS LOAD; BLOOD; COMPUTER SIMULATION; EPIDEMIOLOGY; MIDDLE AGED; MONTE CARLO METHOD; RISK; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL PARAMETERS; VIROLOGY;

ADULT; BIAS (EPIDEMIOLOGY); BIOLOGICAL MARKERS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HIV INFECTIONS; HUMANS; INCIDENCE; LIKELIHOOD FUNCTIONS; LIMIT OF DETECTION; MALE; MIDDLE AGED; MONTE CARLO METHOD; ODDS RATIO; RNA, VIRAL; VIRAL LOAD;

EID: 75349102030     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyp269     Document Type: Article

References (23)

1. Rothman KJ, Greenland S, Lash T. Modern Epidemiology. 3rd edn. New York: Lippincott-Raven, 2008.
2. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
3. Marschner IC, Betensky RA, DeGruttola V, Hammer SM, Kuritzkes DR. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:220-27.
4. Hughes JP. Mixed effects models with censored data with application to HIV RNA levels. Biometrics 1999;55:625-29.
5. Jacqmin-Gadda H, Thiebaut R, Chene G, Commenges D. Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics 2000;1:355-68.
6. Berk KN, Lachenbruch PA. Repeated measures with zeros. Stat Methods Med Res 2002;11:303-16.
7. Thiebaut R, Jacqmin-Gadda H. Mixed models for long-itudinal left-censored repeated measures. Comput Methods Programs Biomed 2004;74:255-60.
8. Lubin JH, Colt JS, Camann D et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect 2004;112:1691-6.
9. Cole SR, Hernán MA, Anastos K, Jamieson BD, Robins JM. Determining the effect of highly active anti-retroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol 2007;166:219-27.
10. Chu H, Gange SJ, Li X et al. Effect of HAART on HIV RNA trajectory among treatment naive men and women: a segmented Bernoulli/lognormal random effects model with left censoring. Epidemiology 2009 (in press).
11. Lynn HS. Maximum likelihood inference for left-censored HIV RNA data. Stat Med 2001;20:33-45.
12. Richardson DB, Ciampi A. Effects of exposure measurement error when an exposure variable is constrained by a lower limit. Am J Epidemiol 2003;157:355-63.
13. Gomez G, Espinal A, Lagakos S. Inference for a linear regression model with an interval-censored covariate. Stat Med 2003;22:409-25.
14. Schisterman EF, Vexler A, Whitcomb BW, Liu A. The limitations due to exposure detection limits for regression models. Am J Epidemiol 2006;163:374-83.
15. Nie L, Chu H, Liu C, Cole SR, Vexler A, Schisterman EF. Linear regression with an independent variable subject to a detection limit. Epidemiology 2009 (in press).
16. Buchacz K, Pan CY, van der Straten A, Hanson CV, Padian N. HIV viral load and viral cultures in sexually active heterosexual men. J Acquir Immune Defic Syndr 2000;23:98-9.
17. Sterne JA, Hernán MA, Ledergerber B et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005;366:378-84.
18. Pawitan Y. In All Likelihood: Statistical Modeling and Inference using Likelihood. New York: Oxford University Press, 2001.
19. Little RJA. Regression with missing Xs: a review. JASA 1992;87:1227-37.
20. Schisterman EF, Reiser B, Faraggi D. ROC analysis for markers with mass at zero. Stat Med 2006;25:623-38.
21. Schisterman EF, Faraggi D, Reiser B, Hu J. Youden Index and the optimal threshold for markers with mass at zero. Stat Med 2008;27:297-315.
22. Little RJA, Rubin DB. Statistical Analysis with Missing Data, 2nd edn. New York: Wiley, 2002.
23. Greenland S. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. Int J Epidemiol 2006;35:765-75.